Neuroendocrine Tumors--Current and Future Clinical Advances

Hematol Oncol Clin North Am. 2016 Feb;30(1):xiii-xiv. doi: 10.1016/j.hoc.2015.09.012. Epub 2015 Oct 20.

Authors

Jennifer A Chan¹, Matthew H Kulke²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address: jang@partners.org.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address: Matthew_Kulke@dfci.harvard.edu.

PMID: 26614379
DOI: 10.1016/j.hoc.2015.09.012

No abstract available

Publication types

Introductory Journal Article

MeSH terms

Biomarkers, Tumor / analysis
Biomarkers, Tumor / genetics
Combined Modality Therapy / methods
Combined Modality Therapy / trends
Disease-Free Survival
Forecasting
Genetic Predisposition to Disease / genetics
Humans
Molecular Imaging / methods*
Molecular Imaging / trends
Molecular Targeted Therapy / methods*
Molecular Targeted Therapy / trends
Mutation
Neuroendocrine Tumors / diagnosis*
Neuroendocrine Tumors / genetics
Neuroendocrine Tumors / therapy*

Substances

Biomarkers, Tumor